NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

I think a weaker NWBO makes that harder. Harder to get the treatment out to more people and more conditions, harder to scale up, harder to reach scale, harder to discount for patients that actually can’t afford it. I’m not saying it has to be exhorbitant, but it is not penicillin either. There is no reason it should be offered below the cost of other treatments when it is so much more complex to manufacture and actually get licensed, and when it does better for patients and literally costs the system far less than other drugs that do less and have more side-effects. It’s like shooting yourself in the foot from day one and then saying hey, we’re going to beat you all. It is not so easily done when you do that and it likely means the company will get bought cheaply and some other company will do what they misguidedly chose not to do. I hope that’s not the case, but I do worry that trying to be cheap, rather than economically consistent with their competitors and the demands of the system of regulation is maybe not the best approach.

I still think they come out at half or less the price of competing drugs that do less ver time.

I’m ran into this challenge when I was a kid. I had a product that lasted 6 times longer than a competitive retail product from larger firms. Small business with some friends. The product not only lasted longer but performed better. But, we did not know that would be the case. We charged half the cost to get started as the original product. Eventually I had to leave for other better things perhaps, and the people I left did not really know how to run it. I sold it for cheap and they did not have the knowledge to understand or run the business.

Had I made the money I think I probably could have at the earlier stages rather than sticking with the initial pricing, like I said, I was just a kid, I probably could have either 1) sold it for many times what I got; or 2) hired better people to run it rather than selling it.

It’s a small example. When you’re already economically pressed, best to stop adding more pressure. Plus I think BP is not likely to want to do great deals if the goal is to give this away at as cheap a price as possible.

There are basic notions about return on capital, and when you have a better product, that is more complicated to make, not underpricing compared to competing products if you want your business to survive. Not saying they are underpricing, but what I am saying is price predictions by shareholders on websites are likely not so great when they assume the company can’t even get licensed when the same folks say it has a better product at a cheaper price already than other licensed products. Those ideas are contradictory. If it’s a better product, that costs less because of how it is administered and lack of side-effects but is complicated to make compared to existing products, why exactly does it need to be even cheaper to qualify for a license? That makes no sense.

This is not an argument against your point. Makes total sense. My point is rather some of the points many have made, suggesting these are the reasons they “can’t get approved”, don’t make any real economic or regulatory sense. The purpose of automation initially should be to accelerate their access to market and earning back capital and getting on a self-sustainable footing that makes them a real drug company. And if they are just going to sell, then getting the best price for the company.